Edition:
United Kingdom

Arbutus Announces Preliminary Early-Stage Clinical Trial Results For AB-506


Monday, 15 Jul 2019 

July 15 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES PRELIMINARY PHASE 1A/1B CLINICAL TRIAL RESULTS FOR AB-506, AN ORAL CAPSID INHIBITOR IN DEVELOPMENT FOR PEOPLE WITH CHRONIC HEPATITIS B.ARBUTUS BIOPHARMA CORP - PHASE 1A/1B CLINICAL TRIAL TO CONTINUE WITH ENROLLMENT OF FURTHER COHORTS.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS OR CLINICALLY SIGNIFICANT SAFETY FINDINGS WERE OBSERVED IN HEALTHY SUBJECTS FOR AB-506.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN CHRONIC HEPATITIS B SUBJECTS. 

Company Quote

1.6
 --
18 Sep 2019